Free Trial

Silk Road Medical (SILK) Stock Price, News & Analysis

-0.70 (-3.08%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
556,737 shs
Average Volume
759,140 shs
Market Capitalization
$869.26 million
P/E Ratio
Dividend Yield
Price Target

Silk Road Medical MarketRank™ Stock Analysis

Analyst Rating
2.18 Rating Score
2.1% Upside
$22.55 Price Target
Short Interest
10.34% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.03mentions of Silk Road Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$351,247 Sold Last Quarter
Proj. Earnings Growth
From ($1.43) to ($1.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

Medical Sector

536th out of 921 stocks

Surgical & Medical Instruments Industry

66th out of 100 stocks

SILK stock logo

About Silk Road Medical Stock (NASDAQ:SILK)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

SILK Stock Price History

SILK Stock News Headlines

Evaluating Silk Road Medical: Insights From 6 Financial Analysts
Silk Road Medical: Q1 Earnings Snapshot
Lake Street Keeps Their Buy Rating on Silk Road Medical (SILK)
SILK Oct 2024 25.000 call
SILK Jul 2024 25.000 call
Argus gets more bullish on Silk Road Medical, upgrades shares
See More Headlines
Receive SILK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silk Road Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$177.13 million
Book Value
$3.88 per share


Free Float
Market Cap
$876.75 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

SILK Stock Analysis - Frequently Asked Questions

Should I buy or sell Silk Road Medical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings
or view top-rated stocks.

What is Silk Road Medical's stock price target for 2024?

11 equities research analysts have issued 1-year price targets for Silk Road Medical's shares. Their SILK share price targets range from $8.00 to $47.00. On average, they expect the company's stock price to reach $22.55 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts price targets for SILK
or view top-rated stocks among Wall Street analysts.

How have SILK shares performed in 2024?

Silk Road Medical's stock was trading at $12.27 at the beginning of 2024. Since then, SILK stock has increased by 80.0% and is now trading at $22.09.
View the best growth stocks for 2024 here

When is Silk Road Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our SILK earnings forecast

How were Silk Road Medical's earnings last quarter?

Silk Road Medical, Inc (NASDAQ:SILK) released its earnings results on Tuesday, April, 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.04. The company had revenue of $48.50 million for the quarter, compared to analysts' expectations of $44.67 million. Silk Road Medical had a negative trailing twelve-month return on equity of 35.47% and a negative net margin of 29.02%. Silk Road Medical's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.43) EPS.

What ETFs hold Silk Road Medical's stock?
What guidance has Silk Road Medical issued on next quarter's earnings?

Silk Road Medical updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $194.0 million-$198.0 million, compared to the consensus revenue estimate of $195.9 million.

What other stocks do shareholders of Silk Road Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include RTX (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

When did Silk Road Medical IPO?

Silk Road Medical (SILK) raised $75 million in an IPO on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Who are Silk Road Medical's major shareholders?

Silk Road Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (11.62%), Capital World Investors (7.89%), Vanguard Group Inc. (7.41%), Bellevue Group AG (3.85%), Bamco Inc. NY (3.80%) and Kennedy Capital Management LLC (2.63%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Kevin J Ballinger, Kevin M Klemz, Lucas W Buchanan, Marie L Jones, Richard Ruedy and Tony M Chou.
View institutional ownership trends

How do I buy shares of Silk Road Medical?

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SILK) was last updated on 5/21/2024 by Staff

From Our Partners